A window into the heterogeneity of human cerebrospinal fluid Aβ peptides

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Ghidoni, Roberta ^a   Paterlini, Anna ^a   Albertini, Valentina ^a   Stoppani, Elena ^a   Binetti, Giuliano ^a   Fuxe, Kjell ^b   Benussi, Luisa ^a   Agnati, Luigi F ^c  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

^c IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-12]; AMYLOID BETA PROTEIN[1-13]; AMYLOID BETA PROTEIN[1-14]; AMYLOID BETA PROTEIN[1-15]; AMYLOID BETA PROTEIN[1-16]; AMYLOID BETA PROTEIN[1-17]; AMYLOID BETA PROTEIN[1-18]; AMYLOID BETA PROTEIN[1-19]; AMYLOID BETA PROTEIN[1-20]; AMYLOID BETA PROTEIN[1-27]; AMYLOID BETA PROTEIN[1-28]; AMYLOID BETA PROTEIN[1-29]; AMYLOID BETA PROTEIN[1-30]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[10-40]; AMYLOID BETA PROTEIN[11-30]; AMYLOID BETA PROTEIN[11-34]; AMYLOID BETA PROTEIN[11-40]; AMYLOID BETA PROTEIN[11-42]; AMYLOID BETA PROTEIN[11-43]; AMYLOID BETA PROTEIN[12-43]; AMYLOID BETA PROTEIN[2-14]; AMYLOID BETA PROTEIN[2-17]; AMYLOID BETA PROTEIN[3-17]; AMYLOID BETA PROTEIN[3-44]; AMYLOID BETA PROTEIN[6-27]; AMYLOID BETA PROTEIN[6-34]; AMYLOID BETA PROTEIN[6-35]; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; CELL SURVIVAL; HUMAN; MICROENVIRONMENT; MOLECULAR PATHOLOGY; NERVE CELL PLASTICITY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN POLYMORPHISM; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; CEREBROSPINAL FLUID;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HUMANS;

EID: 80053492393     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/697036     Document Type: Review

References (113)

1. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L., Beyreuther K., Amyloid plaque core protein in Alzheimer disease and Down syndrome Proceedings of the National Academy of Sciences of the United States of America 1985 82 12 4245 4249 (Pubitemid 15053619)
2. Hardy J., Selkoe D. J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics Science 2002 297 5580 353 356 (Pubitemid 34790756)
3. Lemere C. A., Masliah E., Can Alzheimer disease be prevented by amyloid- immunotherapy? Nature Reviews Neurology 2010 6 2 108 119
4. Haass C., Schlossmacher M. G., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D., Teplow D. B., Selkoe D. J., Amyloid -peptide is produced by cultured cells during normal metabolism Nature 1992 359 6393 322 325
5. Saido T. C., Iwatsubo T., Mann D. M. A., Shimada H., Ihara Y., Kawashima S., Dominant and differential deposition of distinct -amyloid peptide species, A N3(pE), in senile plaques Neuron 1995 14 2 457 466
6. Iwatsubo T., Saido T. C., Mann D. M. A., Lee V. M. Y., Trojanowski J. Q., Full-length amyloid- (1-42(43)) and amino-terminally modified and truncated amyloid- 42(43) deposit in diffuse plaques American Journal of Pathology 1996 149 6 1823 1830 (Pubitemid 26415203)
7. Russo C., Saido T. C., DeBusk L. M., Tabaton M., Gambetti P., Teller J. K., Heterogeneity of water-soluble amyloid -peptide in Alzheimer's disease and Down's syndrome brains FEBS Letters 1997 409 3 411 416 (Pubitemid 27285896)
8. Russo C., Schettini G., Saido T. C., Hulette C., Lippa C., Lannfelt L., Ghetti B., Gambetti P., Tabaton M., Teller J. K., Presenilin-1 mutations in Alzheimer's disease Nature 2000 405 6786 531 532 (Pubitemid 30367716)
9. Portelius E., Bogdanovic N., Gustavsson M. K., Volkmann I., Brinkmalm G., Zetterberg H., Winblad B., Blennow K., Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease Acta Neuropathologica 2010 120 2 185 193
10. Russo C., Salis S., Dolcini V., Amino-terminal modification and tyrosine phosphorylation of carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain Neurobiology of Disease 2001 8 1 173 180 (Pubitemid 32171829)
11. Sergeant N., Bombois S., Ghestem A., Drobecq H., Kostanjevecki V., Missiaen C., Wattez A., David J. P., Vanmechelen E., Sergheraert C., Delacourte A., Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach Journal of Neurochemistry 2003 85 6 1581 1591 (Pubitemid 36702570)
12. Liu K., Solano I., Mann D., Lemere C., Mercken M., Trojanowski J. Q., Lee V. M., Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease Acta neuropathologica 2006 112 2 163 174
13. Sisodia S. S., -Amyloid precursor protein cleavage by a membrane-bound protease Proceedings of the National Academy of Sciences of the United States of America 1992 89 13 6075 6079
14. Vassar R., Bennett B. D., Babu-Khan S., Kahn S., Mendiaz E. A., Denis P., Teplow D. B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M. A., Biere A. L., Curran E., Burgess T., Louis J. C., Collins F., Treanor J., Rogers G., Citron M., -Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE Science 1999 286 5440 735 741
15. Liu K., Doms R. W., Lee V. M. Y., Glu11 site cleavage and N-terminally truncated A production upon BACE overexpression Biochemistry 2002 41 9 3128 3136 (Pubitemid 34184644)
16. Portelius E., Price E., Brinkmalm G., Stiteler M., Olsson M., Persson R., Westman-Brinkmalm A., Zetterberg H., Simon A. J., Blennow K., A novel pathway for amyloid precursor protein processing Neurobiology of Aging 2009 32 6 1090 1098
17. Kametani F., -secretase: reduction of amyloid precursor protein -site cleavage in Alzheimer's disease Current Alzheimer Research 2008 5 2 165 171 (Pubitemid 351536341)
18. Portelius E., Zhang B., Gustavsson M. K., Brinkmalm G., Westman-Brinkmalm A., Zetterberg H., Lee V. M. Y., Trojanowski J. Q., Blennow K., Effects of -secretase inhibition on the amyloid isoform pattern in a mouse model of Alzheimer's disease Neurodegenerative Diseases 2009 6 5-6 258 262
19. McKhann G., Drachman D., Folstein M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology 1984 34 7 939 944 (Pubitemid 14076461)
20. Dubois B., Feldman H. H., Jacova C., DeKosky S. T., Barberger-Gateau P., Cummings J., Delacourte A., Galasko D., Gauthier S., Jicha G., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Stern Y., Visser P. J., Scheltens P., Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurology 2007 6 8 734 746 (Pubitemid 47058377)
21. Dubois B., Feldman H. H., Jacova C., Cummings J. L., DeKosky S. T., Barberger-Gateau P., Delacourte A., Frisoni G., Fox N. C., Galasko D., Gauthier S., Hampel H., Jicha G. A., Meguro K., O'Brien J., Pasquier F., Robert P., Rossor M., Salloway S., Sarazin M., de Souza L. C., Stern Y., Visser P. J., Scheltens P., Revising the definition of Alzheimer's disease: a new lexicon The Lancet Neurology 2010 9 11 1118 1127
22. McKhann G. M., Knopman D. S., Chertkow H., Hyman B. T., Jack Jr. C. R., Kawas C. H., Klunk W. E., Koroshetz W. J., Manly J. J., Mayeux R., Mohs R. C., Morris J. C., Rossor M. N., Scheltens P., Carrillo M. C., Thies B., Weintraub S., Phelps C. H., The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimer's and Dementia 2011 7 3 263 269
23. Albert M. S., DeKosky S. T., Dickson D., Dubois B., Feldman H. H., Fox N. C., Gamst A., Holtzman D. M., Jagust W. J., Petersen R. C., Snyder P. J., Carrillo M. C., Thies B., Phelps C. H., The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimer's and Dementia 2011 7 3 270 279
24. Sperling R. A., Aisen P. S., Beckett L. A., Bennett D. A., Craft S., Fagan A. M., Iwatsubo T., Jack Jr. C. R., Kaye J., Montine T. J., Park D. C., Reiman E. M., Rowe C. C., Siemers E., Stern Y., Yaffe K., Carrillo M. C., Thies B., Morrison-Bogorad M., Wagster M. V., Phelps C. H., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimer's and Dementia 2011 7 3 280 292
25. Blennow K., Hampel H., Weiner M., Zetterberg H., Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nature Reviews Neurology 2010 6 3 131 144
26. Mattsson N., Zetterberg H., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S. K., Van Der Flier W. M., Blankenstein M. A., Ewers M., Rich K., Kaiser E., Verbeek M., Tsolaki M., Mulugeta E., Rosén E., Aarsland D., Jelle Visser P., Schrder J., Marcusson J., De Leon M., Hampel H., Scheltens P., Pirttil T., Wallin A., Eriksdotter Jnhagen M., Minthon L., Winblad B., Blennow K., CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment Journal of the American Medical Association 2009 302 4 385 393
27. Visser P. J., Verhey F., Knol D. L., Scheltens P., Wahlund L. O., Freund-Levi Y., Tsolaki M., Minthon L., Wallin. K., Hampel H., Brger K., Pirttila T., Soininen H., Rikkert M. O., Verbeek M. M., Spiru L., Blennow K., Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study The Lancet Neurology 2009 8 7 619 627
28. Shaw L. M., Vanderstichele H., Knapik-Czajka M., Clark C. M., Aisen P. S., Petersen R. C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V. M. Y., Trojanowski J. Q., Cerebrospinal fluid biomarker signature in alzheimer's disease neuroimaging initiative subjects Annals of Neurology 2009 65 4 403 413
29. Frisoni G. B., Prestia A., Zanetti O., Galluzzi S., Romano M., Cotelli M., Gennarelli M., Binetti G., Bocchio L., Paghera B., Amicucci G., Bonetti M., Benussi L., Ghidoni R., Geroldi C., Markers of Alzheimer's disease in a population attending a memory clinic Alzheimer's and Dementia 2009 5 4 307 317
30. Galluzzi S., Geroldi C., Ghidoni R., Paghera B., Amicucci G., Bonetti M., Zanetti O., Cotelli M., Gennarelli M., Frisoni G. B., Translational outpatient memory clinic working group. The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment Journal of Neurology 2010 257 12 2004 2014
31. Kanai M., Matsubara E., Isoe K., Urakami K., Nakashima K., Arai H., Sasaki H., Abe K., Iwatsubo T., Kosaka T., Watanabe M., Tomidokoro Y., Shizuka M., Mizushima K., Nakamura T., Igeta Y., Ikeda Y., Amari M., Kawarabayashi T., Ishiguro K., Harigaya Y., Wakabayashi K., Okamoto K., Hirai S., Shoji M., Longitudinal study of cerebrospinal fluid levels of tau, A 1-40, and A 1-42(43) in Alzheimer's disease: a study in Japan Annals of Neurology 1998 44 1 17 26 (Pubitemid 28323651)
32. Mehta P. D., Pirttil T., Mehta S. P., Sersen E. A., Aisen P. S., Wisniewski H. M., Plasma and cerebrospinal fluid levels of amyloid proteins 1-40 and 1- 42 in Alzheimer disease Archives of Neurology 2000 57 1 100 105 (Pubitemid 30027637)
33. Fukuyama R., Mizuno T., Mizuno T., Mori S., Nakajima K., Fushiki S., Yanagisawa K., Age-dependent change in the levels of A 40 and A 42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of A 42 to A 40 level in cerebrospinal fluid from Alzheimer's disease patients European Neurology 2000 43 3 155 160 (Pubitemid 30189537)
34. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., Blennow K., Prediction of Alzheimer's disease using the CSF A 42/A 40 ratio in patients with mild cognitive impairment Dementia and Geriatric Cognitive Disorders 2007 23 5 316 320 (Pubitemid 46631938)
35. Fagan A. M., Head D., Shah A. R., Marcus D., Mintun M., Morris J. C., Holtzman D. M., Decreased cerebrospinal fluid A 42 correlates with brain atrophy in cognitively normal elderly Annals of Neurology 2009 65 2 176 183
36. Roe C. M., Fagan A. M., Williams M. M., Ghoshal N., Aeschleman M., Grant E. A., Marcus D. S., Mintun M. A., Holtzman D. M., Morris J. C., Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease Neurology 2011 76 6 501 510
37. Rolstad S., Berg A. I., Bjerke M., Amyloid- 42 is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. Journal of Alzheimers Disease,. In press
38. Cedazo-Minguez A., Winblad B., Biomarkers for Alzheimer's disease and other forms of dementia: clinical needs, limitations and future aspects Experimental Gerontology 2010 45 1 5 14
39. Bibl M., Mollenhauer B., Wolf S., Esselmann H., Lewczuk P., Kornhuber J., Wiltfang J., Reduced CSF carboxyterminally truncated A peptides in frontotemporal lobe degenerations Journal of Neural Transmission 2007 114 5 621 628 (Pubitemid 46664055)
40. Bibl M., Mollenhauer B., Esselmann H., Lewczuk P., Trenkwalder C., Brechlin P., Rther E., Kornhuber J., Otto M., Wiltfang J., CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies Journal of Neural Transmission 2006 113 11 1771 1778 (Pubitemid 44657673)
41. Andreasen N., Zetterberg H., Amyloid-related biomarkers for Alzheimer's disease Current Medicinal Chemistry 2008 15 8 766 771 (Pubitemid 351516792)
42. Gowing E., Roher A. E., Woods A. S., Cotter R. J., Chaney M., Little S. P., Ball M. J., Chemical characterization of A 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease Journal of Biological Chemistry 1994 269 15 10987 10990
43. Nslund J., Schierhorn A., Hellman U., Lannfelt L., Roses A. D., Tjernberg L. O., Silberring J., Gandy S. E., Winblad B., Greengard P., Nordstedt C., Terenius L., Relative abundance of Alzheimer A amyloid peptide variants in Alzheimer disease and normal aging Proceedings of the National Academy of Sciences of the United States of America 1994 91 18 8378 8382 (Pubitemid 24273667)
44. Harigaya Y., Saido T. C., Eckman C. B., Prada C. M., Shoji M., Younkin S. G., Amyloid protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain Biochemical and Biophysical Research Communications 2000 276 2 422 427
45. Miravalle L., Calero M., Takao M., Roher A. E., Ghetti B., Vidal R., Amino-terminally truncated A peptide species are the main component of cotton wool plaques Biochemistry 2005 44 32 10810 10821 (Pubitemid 41153641)
46. Piccini A., Russo C., Gliozzi A., Relini A., Vitali A., Borghi R., Giliberto L., Armirotti A., D'Arrigo C., Bachi A., Cattaneo A., Canale C., Torrassa S., Saido T. C., Markesbery W., Gambetti P., Tabaton M., -amyloid is different in normal aging and in Alzheimer disease Journal of Biological Chemistry 2005 280 40 34186 34192 (Pubitemid 41443143)
47. Portelius E., Westman-Brinkmalm A., Zetterberg H., Blennow K., Determination of -amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry Journal of Proteome Research 2006 5 4 1010 1016
48. Portelius E., Tran A. J., Andreasson U., Persson R., Brinkmann G., Zetterberg H., Blennow K., Westman-Brinkmalm A., Characterization of amyloid peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry Journal of Proteome Research 2007 6 11 4433 4439 (Pubitemid 350158518)
49. Portelius E., Andreasson U., Ringman J. M., Buerger K., Daborg J., Buchhave P., Hansson O., Harmsen A., Gustavsson M. K., Hanse E., Galasko D., Hampel H., Blennow K., Zetterberg H., Distinct cerebrospinal fluid amyloid peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease Molecular Neurodegeneration 2010 5 1, article 2
50. Maddalena A. S., Papassotiropoulos A., Gonzalez-Agosti C., Signorell A., Hegi T., Pasch T., Nitsch R. M., Hock C., Cerebrospinal fluid profile of amyloid peptides in patients with Alzheimer's disease determined by protein biochip technology Neurodegenerative Diseases 2004 1 4-5 231 235 (Pubitemid 39551802)
51. Albertini V., Bruno A., Paterlini A., Lista S., Benussi L., Cereda C., Binetti G., Ghidoni R., Optimization protocol for amyloid- peptides detection in human cerebrospinal fluid using SELDI TOF MS Proteomics-Clinical Applications 2010 4 3 352 357
52. Portelius E., Zetterberg H., Andreasson U., Brinkmalm G., Andreasen N., Wallin A., Westman-Brinkmalm A., Blennow K., An Alzheimer's disease-specific -amyloid fragment signature in cerebrospinal fluid Neuroscience Letters 2006 409 3 215 219 (Pubitemid 44648565)
53. Vigo-Pelfrey C., Lee D., Keim P., Lieberburg I., Schenk D. B., Characterization of -amyloid peptide from human cerebrospinal fluid Journal of Neurochemistry 1993 61 5 1965 1968 (Pubitemid 23317227)
54. Ghidoni R., Albertini V., Squitti R., Paterlini A., Bruno A., Bernardini S., Cassetta E., Rossini P. M., Squitieri F., Benussi L., Binetti G., Novel T719P A PP mutation unbalances the relative proportion of amyloid- peptides Journal of Alzheimer's Disease 2009 18 2 295 303
55. Lewczuk P., Esselmann H., Meyer M., Wollscheid V., Neumann M., Otto M., Maler J. M., Rther E., Kornhuber J., Wiltfang J., The amyloid- (A ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated A peptide Rapid Communications in Mass Spectrometry 2003 17 12 1291 1296 (Pubitemid 36750013)
56. Vanderstichele H., De Meyer G., Andreasen N., Kostanjevecki V., Wallin A., Olsson A., Blennow K., Vanmechelen E., Amino-truncated -amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment Clinical Chemistry 2005 51 9 1650 1660 (Pubitemid 41233100)
57. Wiltfang J., Esselmann H., Bibl M., Smirnov A., Otto M., Paul S., Schmidt B., Klafki H. W., Maler M., Dyrks T., Bienert M., Beyermann M., Rther E., Kornhuber J., Highly conserved and disease-specific patterns of carboxyterminally truncated A peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation Journal of Neurochemistry 2002 81 3 481 496 (Pubitemid 34809327)
58. Lewczuk P., Esselmann H., Groemer T. W., Bibl M., Maler J. M., Steinacker P., Otto M., Kornhuber J., Wiltfang J., Amyloid peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease Biological Psychiatry 2004 55 5 524 530 (Pubitemid 38338541)
59. Portelius E., Dean R. A., Gustavsson M. K., A novel abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease Alzheimers Research Theraphy 2010 2 7 1 7
60. Walsh D. M., Selkoe D. J., A oligomersa decade of discovery Journal of Neurochemistry 2007 101 5 1172 1184
61. Xia W., Yang T., Shankar G., Smith I. M., Shen Y., Walsh D. M., Selkoe D. J., A specific enzyme-linked immunosorbent assay for measuring -amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer Disease Archives of Neurology 2009 66 2 190 199
62. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L., Wals P., Zhang C., Finch C. E., Krafft G. A., Klein W. L., Diffusible, nonfibrillar ligands derived from A 1-42 are potent central nervous system neurotoxins Proceedings of the National Academy of Sciences of the United States of America 1998 95 11 6448 6453
63. Hartley D. M., Walsh D. M., Ye C. P., Diehl T., Vasquez S., Vassilev P. M., Teplow D. B., Selkoe D. J., Protofibrillar intermediates of amyloid -protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons Journal of Neuroscience 1999 19 20 8876 8884 (Pubitemid 30226709)
64. Kayed R., Sokolov Y., Edmonds B., McIntire T. M., Milton S. C., Hall J. E., Glabe C. G., Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases Journal of Biological Chemistry 2004 279 45 46363 46366 (Pubitemid 39518276)
65. Mucke L., Masliah E., Yu G. Q., Mallory M., Rockenstein E. M., Tatsuno G., Hu K., Kholodenko D., Johnson-Wood K., McConlogue L., High-level neuronal expression of A (1-42) in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation Journal of Neuroscience 2000 20 11 4050 4058 (Pubitemid 30365675)
66. Lesné S., Ming T. K., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M., Ashe K. H., A specific amyloid- protein assembly in the brain impairs memory Nature 2006 440 7082 352 357
67. Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J., Selkoe D. J., Naturally secreted oligomers of amyloid protein potently inhibit hippocampal long-term potentiation in vivo Nature 2002 416 6880 535 539 (Pubitemid 34288854)
68. Klyubin I., Walsh D. M., Lemere C. A., Cullen W. K., Shankar G. M., Betts V., Spooner E. T., Jiang L., Anwyl R., Selkoe D. J., Rowan M. J., Amyloid protein immunotherapy neutralizes A oligomers that disrupt synaptic plasticity in vivo Nature Medicine 2005 11 5 556 561 (Pubitemid 40685979)
69. Shankar G. M., Li S., Mehta T. H., Garcia-Munoz A., Shepardson N. E., Smith I., Brett F. M., Farrell M. A., Rowan M. J., Lemere C. A., Regan C. M., Walsh D. M., Sabatini B. L., Selkoe D. J., Amyloid- protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory Nature Medicine 2008 14 8 837 842
70. Reed M. N., Hofmeister J. J., Jungbauer L., Cognitive effects of cell-derived and synthetically derived Abeta oligomers Neurobiology of Aging 2011 32 10 1784 1794
71. Li S., Jin M., Koeglsperger T., Shepardson N. E., Shankar G. M., Selkoe D. J., Soluble a oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors Journal of Neuroscience 2011 31 18 6627 6638
72. Pitschke M., Prior R., Haupt M., Riesner D., Detection of single amyloid -protein aggregates in the cerebrospinal fluid of Alzheirner's patients by fluorescence correlation spectroscopy Nature Medicine 1998 4 7 832 834 (Pubitemid 28331026)
73. Georganopoulou D. G., Chang L., Nam J. M., Thaxton C. S., Mufson E. J., Klein W. L., Mirkin C. A., Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2005 102 7 2273 2276 (Pubitemid 40279365)
74. Santos A. N., Torkler S., Nowak D., Schlittig C., Goerdes M., Lauber T., Trischmann L., Schaupp M., Penz M., Tiller F. W., Bhm G., Detection of amyloid- oligomers in human cerebrospinal fluid by flow cytometry and fluorescence resonance energy transfer Journal of Alzheimer's Disease 2007 11 1 117 125 (Pubitemid 46376713)
75. Klyubin I., Betts V., Welzel A. T., Blennow K., Zetterberg H., Wallin A., Lemere C. A., Cullen W. K., Peng Y., Wisniewski T., Selkoe D. J., Anwyl R., Walsh D. M., Rowan M. J., Amyloid protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization Journal of Neuroscience 2008 28 16 4231 4237
76. Englund H., Gunnarsson M. D., Brundin R. M., Hedlund M., Kilander L., Lannfelt L., Pettersson F. E., Oligomerization partially explains the lowering of A 42 in alzheimer's disease cerebrospinal fluid Neurodegenerative Diseases 2009 6 4 139 147
77. Fukumoto H., Tokuda T., Kasai T., High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients The Journal the Federation of American Societies for Experimental Biology 2010 24 8 2716 2726
78. Gao C. M., Yam A. Y., Magdangal E., Wang X., Salisbury C., Peretz D., Zuckermann R. N., Connolly M. D., Hansson O., Minthon L., Zetterberg H., Blennow K., Fedynyshyn J. P., Allauzen S., A 40 oligomers identified as a potential biomarker for the diagnosis of alzheimer's disease PLoS One 2010 5 12
79. Kayed R., Head E., Thompson J. L., McIntire T. M., Milton S. C., Cotman C. W., Glabel C. G., Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis Science 2003 300 5618 486 489 (Pubitemid 36444329)
80. O'Nuallain B., Wetzel R., Conformational Abs recognizing a generic amyloid fibril epitope Proceedings of the National Academy of Sciences of the United States of America 2002 99 3 1485 1490 (Pubitemid 34136519)
81. Lambert M. P., Velasco P. T., Chang L., Viola K. L., Fernandez S., Lacor P. N., Khuon D., Gong Y., Bigio E. H., Shaw P., De Felice F. G., Krafft G. A., Klein W. L., Monoclonal antibodies that target pathological assemblies of A Journal of Neurochemistry 2007 100 1 23 35 (Pubitemid 46085837)
82. Habicht G., Haupt C., Friedrich R. P., Hortschansky P., Sachse C., Meinhardt J., Wieligmann K., Gellermann G. P., Brodhun M., Gtz J., Halbhuber K. J., Rcken C., Horn U., Fndrich M., Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing A protofibrils Proceedings of the National Academy of Sciences of the United States of America 2007 104 49 19232 19237
83. Meli G., Visintin M., Cannistraci I., Cattaneo A., Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid- oligomers Journal of Molecular Biology 2009 387 3 584 606
84. Agnati L. F., Leo G., Genedani S., Piron L., Rivera A., Guidolin D., Fuxe K., Common key-signals in learning and neurodegeneration: focus on excito-amino acids, -amyloid peptides and -synuclein Journal of Neural Transmission 2009 116 8 953 974
85. Agnati L. F., Fuxe K., Volume transmission as a key feature of information handling in the central nervous system possible new interpretative value of the Turing's B-type machine Progress in Brain Research 2000 125 3 19 (Pubitemid 35460791)
86. Lakkaraju A., Rodriguez-Boulan E., Itinerant exosomes: emerging roles in cell and tissue polarity Trends in Cell Biology 2008 18 5 199 209
87. Cocucci E., Racchetti G., Meldolesi J., Shedding microvesicles: artefacts no more Trends in Cell Biology 2009 19 2 43 51
88. Simons M., Raposo G., Exosomesvesicular carriers for intercellular communication Current Opinion in Cell Biology 2009 21 4 575 581
89. Rustom A., Hen or egg? Some thoughts on tunneling nanotubes Annals of the New York Academy of Sciences 2009 1178 129 136
90. Agnati L. F., Genedani S., Leo G., Forni A., Woods A. S., Filaferro M., Franco R., Fuxe K., A peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer's disease Journal of Neural Transmission 2007 114 1 21 31 (Pubitemid 46018672)
91. Vekrellis K., Ye Z., Qiu W. Q., Walsh D., Hartley D., Chesneau V., Rosner M. R., Selkoe D. J., Neurons regulate extracellular levels of amyloid -protein via proteolysis by insulin-degrading enzyme Journal of Neuroscience 2000 20 5 1657 1665 (Pubitemid 30220363)
92. Hock C., Golombowski S., Mller-Spahn F., Naser W., Beyreuther K., Mnning U., Schenk D., Vigo-Pelfrey C., Bush A. M., Moir R., Tanzi R. E., Growdon J. H., Nitsch R. M., Cerebrospinal fluid levels of amyloid precursor protein and amyloid -peptide in Alzheimer's disease and major depressioninverse correlation with dementia severity European Neurology 1998 39 2 111 118 (Pubitemid 28069802)
93. Funke S. A., Birkmann E., Willbold D., Detection of amyloid- aggregates in body fluids: a suitable method for early diagnosis of Alzheimer's disease? Current Alzheimer Research 2009 6 3 285 289
94. Oe T., Ackermann B. L., Inoue K., Berna M. J., Garner C. O., Gelfanova V., Dean R. A., Siemers E. R., Holtzman D. M., Farlow M. R., Blair I. A., Quantitative analysis of amyloid peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry Rapid Communications in Mass Spectrometry 2006 20 24 3723 3735 (Pubitemid 44935325)
95. Rajendran L., Honsho M., Zahn T. R., Keller P., Geiger K. D., Verkade P., Simons K., Alzheimer's disease -amyloid peptides are released in association with exosomes Proceedings of the National Academy of Sciences of the United States of America 2006 103 30 11172 11177 (Pubitemid 44156491)
96. Vingtdeux V., Hamdane M., Loyens A., Gelé P., Drobeck H., Bégard S., Galas M. C., Delacourte A., Beauvillain J. C., Buée L., Sergeant N., Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies Journal of Biological Chemistry 2007 282 25 18197 18205 (Pubitemid 47100204)
97. Sharples R. A., Vella L. J., Nisbet R. M., Naylor R., Perez K., Barnham K. J., Masters C. L., Hill A. F., Inhibition of -secretase causes increased secretion of amyloid precursor protein C-terminal fragments in association with exosomes The Journal of the Federation of American Societies for Experimental Biology 2008 22 5 1469 1478 (Pubitemid 351656787)
98. Ghidoni R., Benussi L., Binetti G., Exosomes: the Trojan horses of neurodegeneration Medical Hypotheses 2008 70 6 1226 1227
99. Ghidoni R., Paterlini A., Albertini V., Glionna M., Monti E., Schiaffonati L., Benussi L., Levy E., Binetti G., Cystatin C is released in association with exosomes: a new tool of neuronal communication which is unbalanced in Alzheimer's disease Neurobiology of Aging 2009 32 8 1435 1442
100. Agnati L. F., Guidolin D., Baluka F., Leo G., Barlow P. W., Carone C., Genedani S., A new hypothesis of pathogenesis based on the divorce between mitochondria and their host cells: possible relevance for alzheimer's disease Current Alzheimer Research 2010 7 4 307 322
101. Chi E. Y., Frey S. L., Lee K. Y. C., Ganglioside GM1-mediated amyloid-beta fibrillogenesis and membrane disruption Biochemistry 2007 46 7 1913 1924
102. Yuyama K., Yamamoto N., Yanagisawa K., Accelerated release of exosome-associated GM1 ganglioside (GM1) by endocytic pathway abnormality: another putative pathway for GM1-induced amyloid fibril formation Journal of Neurochemistry 2008 105 1 217 224 (Pubitemid 351441638)
103. Re R. N., Cook J. L., Senescence, apoptosis, and stem cell biology: the rationale for an expanded view of intracrine action American Journal of Physiology, Heart and Circulatory Physiology 2009 297 3 H893 H901
104. Lai A. Y., McLaurin J., Mechanisms of amyloid-beta peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins International Journal of Alzheimer's Disease 2011 2011 11
105. Pearson H. A., Peers C., Physiological roles for amyloid peptides Journal of Physiology 2006 575 1 5 10
106. Garcia-Osta A., Alberini C. M., Amyloid beta mediates memory formation Neurobiology of Learning and Memory 2009 16 4 267 272
107. Soscia S. J., Kirby J. E., Washicosky K. J., Tucker S. M., Ingelsson M., Hyman B., Burton M. A., Goldstein L. E., Duong S., Tanzi R. E., Moir R. D., The Alzheimer's disease-associated amyloid -protein is an antimicrobial peptide PLoS One 2010 5 3 1 10
108. Tanzi E., I fatti e le induzione nellodierna istologia del sistema nervoso Rivista sperimentale di freniatria e medicina legale delle alienazioni mentali 1893 19 419 472
109. Taylor J. S., Gaze R. M., The effects of the fibre environment on the paths taken by regenerating optic nerve fibres in Xenopus Journal of Embryology and Experimental Morphology 1985 89 383 401 (Pubitemid 16211100)
110. Agnati L. F., Zoli M., Biagini G., Fuxe K., Neuronal plasticity and ageing processes in the frame of the 'Red Queen Theory' Acta Physiologica Scandinavica 1992 145 4 301 309
111. Yamada K., Nabeshima T., Brain-derived neurotrophic factor/TrkB signaling in memory processes Journal Pharmacological Sciences 2003 91 4 267 270 (Pubitemid 36581946)
112. Schindowski K., Belarbi K., Buée L., Neurotrophic factors in Alzheimer's disease: role of axonal transport Genes, Brain and Behavior 2008 7 1 43 56
113. Tuppo E. E., Arias H. R., The role of inflammation in Alzheimer's disease International Journal of Biochemistry and Cell Biology 2005 37 2 289 305 (Pubitemid 39330191)